Please note: The information displayed on this page might be outdated.
Arvelle Therapeutics: Arvelle Therapeutics is an emerging biopharmaceutical company focused on bringing innovative solutions to patients suffering from CNS disorders. Arvelle is responsible for the development and commercialization of cenobamate, an investigational antiepileptic drug, in the European market. Arvelle is headquartered in Switzerland and received start-up financing of $207.8 million, one of the largest initial financing commitments for a European-focused biopharmaceutical company, with investments from a global syndicate including NovaQuest Capital Management, BRV Capital Management, LSP, H.I.G. BioHealth Partners, Andera Partners, F-Prime Capital and KB Investments.
Sector/Industry:
Healthcare/Biotechnology
Characteristics:
Based in...
Europe
Clinical Stage
Phase III, Phase l or ll
Disease Space
Central Nervous System, Rare Disease
Industry
Biotechnology
Listing
Private
Market Cap
100MM - 500MM
Website:
Profiles:
Address:
Basel
Switzerland

Company Participants at European Biotech Investor Day 2020

  • Mark Altmeyer, CEO

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.

Upcoming Company Event Participation

Fall Private Company Showcase 2020

VIRTUAL, October 15, 2020